OTS447

CAS No. 1356943-67-3

OTS447( —— )

Catalog No. M35684 CAS No. 1356943-67-3

OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 192 Get Quote
5MG 297 Get Quote
10MG 471 Get Quote
25MG 877 Get Quote
50MG 1408 Get Quote
100MG 2142 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    OTS447
  • Note
    Research use only, not for human use.
  • Brief Description
    OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .
  • Description
    OTS447 is a potent FLT3 inhibitor with an IC50 of 21 nM (WO2012016082A1, compound 335).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    FLT
  • Recptor
    FLT
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1356943-67-3
  • Formula Weight
    466.02
  • Molecular Formula
    C27H32ClN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 12.41 mg/mL (26.63 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)
  • SMILES
    CCN(CC)C1CCC(CC1)Nc1c(cnc2ccc(cc12)-c1ccc(O)c(Cl)c1)C(C)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yo Matsuo, et al. Quinoline derivatives and melk inhibitors containing the same. WO2012016082A1.
molnova catalog
related products
  • FLT3-IN-2

    FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM.

  • BGB-102

    BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.

  • FLT3-IN-10

    FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).